-
1 Comment
Jinyu Bio-technology Co., Ltd is currently in a long term downtrend where the price is trading 17.0% below its 200 day moving average.
From a valuation standpoint, the stock is 60.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Jinyu Bio-technology Co., Ltd's total revenue rose by 43.6% to $483M since the same quarter in the previous year.
Its net income has increased by 44.4% to $113M since the same quarter in the previous year.
Finally, its free cash flow grew by 1691.8% to $218M since the same quarter in the previous year.
Based on the above factors, Jinyu Bio-technology Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| ISIN | CNE000000Y37 |
| Sector | Healthcare |
| Dividend Yield | 0.4% |
|---|---|
| Beta | 0.69 |
| Market Cap | 9B |
| PE Ratio | 162.6 |
| Target Price | 7.18 |
Jinyu Bio-technology Co., Ltd. develops and evaluates vaccines and reagents for animal diseases. It offers vaccines for pigs to treat swine influenza, g E gene deletion, classical swine fever, porcine parvovirus and circovirus, foot-and-mouth disease, porcine reproductive and respiratory syndrome, pseudorabies, swine erysipelas, porcine pasteurella multocida triple foot-and-mouth disease type 0, swine erysipelas, porcine pasteurella multocida, porcine paratyphoid porcine circovirus, and porcine escherichia coli; ruminants vaccines for the treatment of foot-and-mouth disease type O and type A, bovine viral diarrhea/mucosal disease, infectious rhinotracheitis, goat pox, brucellosis, sheep plague, sudden death, lamb dysentery, and enterotoxemia. The company also sells poultry vaccines to treat recombinant avian influenza virus, Newcastle disease, infectious bronchitis, egg drop syndrome, avian influenza (H9 subtype), infectious bursal disease, infectious bronchitis, duck tembusu virus disease, and recombinant Newcastle disease virus; inactivated rabies vaccine; and diagnostic reagents, including foot-and-mouth disease type O liquid phase blocking ELISA antibody detection kit, foot-and-mouth disease type A liquid phase blocking ELISA antibody detection kit, classical swine fever E2 protein ELISA antibody detection kit, and foot-and-mouth disease type A virus monoclonal antibody competitive ELISA detection kit. In addition, it provides needle free injection, combined immunization, epidemic prevention guide, and diagnostic testing services. The company was founded in 1992 and is headquartered in Hohhot, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600201.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
